Literature DB >> 12114875

Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of (18)F-FDG PET.

E C S C Etchebehere1, H A Macapinlac, M Gonen, K Humm, H W D Yeung, T Akhurst, H I Scher, S M Larson.   

Abstract

BACKGROUND: Recently, iterative reconstruction with segmented attenuation corrections (IRSAC) has been introduced for reconstruction of (18)F-FDG PET images. IRSAC produces images that are more pleasing to the eye, but qualitative and quantitative comparisons between IRSAC and filtered back projection (FBP) have not been reported for metastatic cancer. Since quantitative data has been widely used as an adjunct to interpretation of PET scans, comparison between IRSAC and FBP is needed. The purpose of this study was to compare image quality and the maximum standardized uptake value (SUVmax) obtained with FBP and with IRSAC in metastatic lesions from prostate cancer.
METHODS: Twenty (18)F-FDG PET scans (10 baseline and 10 follow-up) were performed in 10 patients with prostate cancer (ages 66-85 yrs, mean 73.6 yrs). Acquisition began 45 min after injection of 370 MBq of (18)F-FDG. Images were reconstructed using FBP and IRSAC, and submitted to visual and quantitative analysis. SUVmax was obtained for all metastases, on FBP and IRSAC. A Jaszczak phantom study was also performed.
RESULTS: IRSAC images showed better image quality than FBP especially in regions of high activity concentrations. IRSAC detected 106 lesions on both baseline and follow-up scans, while FBP detected 100 and 95 lesions on baseline and follow-up scans, respectively. Therefore, 17 more lesions were seen on IRSAC. The mean SUVmax values on baseline scans for FBP and IRSAC were systematically different, at 4.46+/-1.99 and 5.13+/-2.67, respectively. On follow-up scans values were 3.89+/-1.72 for FBP and 4.29+/-1.93 for IRSAC. Comparison of FBP with IRSAC on baseline and follow-up scans were statistically significant (baseline: paired "t"-test p=0.0017; follow-up: paired "t"-test p=0.0008). Phantom studies reveal that these differences can be explained by the type of reconstruction filters used, and IRSAC was more accurate than FBP.
CONCLUSIONS: IRSAC detects smaller volumes in phantoms, patient images are easier to interpret and more metastatic lesions were detected. In addition, IRSAC provides reproducible quantitative data, comparable to data provided by FBP. IRSAC SUV and FBP SUV are in close agreement but there was a statistically significant difference between the two, and therefore threshold values of SUV will probably need to be re-determined with IRSAC, and are likely to be 10 to 19% higher than currently reported.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12114875

Source DB:  PubMed          Journal:  Q J Nucl Med        ISSN: 1125-0135


  10 in total

1.  FDG PET in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  PET Clin       Date:  2009-04-01

2.  Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial.

Authors:  Nanda C Krak; R Boellaard; Otto S Hoekstra; Jos W R Twisk; Corneline J Hoekstra; Adriaan A Lammertsma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-15       Impact factor: 9.236

3.  Optimised PET reconstruction of the head and neck area: improved diagnostic accuracy.

Authors:  Wouter V Vogel; Bart M Wensing; Jorn A van Dalen; Paul F M Krabbe; Frank J A van den Hoogen; Wim J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07-16       Impact factor: 9.236

4.  Forced diuresis and dual-phase F-fluorodeoxyglucose-PET/CT scan for restaging of urinary bladder cancers.

Authors:  S Harkirat; Ss Anand; Mj Jacob
Journal:  Indian J Radiol Imaging       Date:  2010-02

Review 5.  Methodological considerations in quantification of oncological FDG PET studies.

Authors:  Dennis Vriens; Eric P Visser; Lioe-Fee de Geus-Oei; Wim J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-20       Impact factor: 9.236

6.  [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland.

Authors:  Hossein Jadvar; Wei Ye; Susan Groshen; Peter S Conti
Journal:  Ann Nucl Med       Date:  2008-11-28       Impact factor: 2.668

Review 7.  Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET.

Authors:  Hossein Jadvar
Journal:  Nat Rev Urol       Date:  2009-05-12       Impact factor: 14.432

Review 8.  Attenuation-corrected vs. nonattenuation-corrected 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in oncology: a systematic review.

Authors:  Urvi Joshi; Pieter G H M Raijmakers; Ingrid I Riphagen; Gerrit J J Teule; Arthur van Lingen; Otto S Hoekstra
Journal:  Mol Imaging Biol       Date:  2007 May-Jun       Impact factor: 3.488

9.  O-(2-[18F]fluoroethyl)-L-tyrosine PET in gliomas: influence of data processing in different centres.

Authors:  Christian P Filss; Nathalie L Albert; Guido Böning; Elena Rota Kops; Bogdana Suchorska; Gabriele Stoffels; Norbert Galldiks; Nadim J Shah; Felix M Mottaghy; Peter Bartenstein; Jörg C Tonn; Karl-Josef Langen
Journal:  EJNMMI Res       Date:  2017-08-16       Impact factor: 3.138

10.  Quantitative performance and optimal regularization parameter in block sequential regularized expectation maximization reconstructions in clinical 68Ga-PSMA PET/MR.

Authors:  Edwin E G W Ter Voert; Urs J Muehlematter; Gaspar Delso; Daniele A Pizzuto; Julian Müller; Hannes W Nagel; Irene A Burger
Journal:  EJNMMI Res       Date:  2018-07-27       Impact factor: 3.138

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.